 |
|
|
|
|
|
NEWS RELEASE:
FOR IMMEDIATE RELEASE:
|
Contact:
Jacques Cornet, VP of Business Development & Strategic Marketing
Cedara Software Corp.
905.672.2100 x-2564 jacques.cornet@cedara.com |
|
Media Contact:
Beth Frost-Johnson, Sr. VP of Marketing
Merge Healthcare
(414) 977-4254
bethfj@merge.com
|
|
Attention: Business/Financial Editors:
CEDARA SOFTWARE SIGNS KEY PURCHASE AGREEMENT FOR DIGITAL ORTHOPAEDICS SOLUTION
Toronto, ON, March 22, 2006 – Cedara Software, a Merge Healthcare company (Nasdaq: MRGE; TSX: MRG) and a leading independent developer of medical software technologies for the global healthcare market, today announced an agreement with Mayo Clinic to provide Cedara’s OrthoWorks digital planning software to orthopaedic surgeons.
OrthoWorks products will be used in conjunction with Mayo Clinic’s existing PACS infrastructure, providing tools to support digital orthopedic planning within Mayo Clinic’s diverse orthopedic surgery practice.
Cedara OrthoWorks represents a unique breadth and depth of technology in digital radiography, providing coverage to a variety of specialty domains within the field of orthopaedics. OrthoWorks includes dedicated functionality for joint arthroplasty, spine, trauma, deformity corrections, image manipulation, image stitching and more. Cedara’s capabilities and expertise for integration allows OrthoWorks to operate in support of clinical workflow and PACS infrastructure.
“We are very pleased to work with Mayo in support of digital orthopaedic planning,” said Brian Pedlar, President of Cedara Software, “Their Department of Orthopaedic Surgery is a recognized global leader in orthopaedic medicine."
Cedara Software will be present at the annual meeting of the American Academy of Orthopaedic Surgeons (AAOS) from March 22-24, at booth 2455 in the South Hall of McCormick Place in Chicago, Illinois.
# # #
Cedara Software is a Merge Healthcare company focused on the development of custom engineered software applications and development tools for the medical imaging OEM and International markets. Cedara software is deployed in hospitals and clinics worldwide and is licensed by many of the world's leading medical device and healthcare information technology companies. Cedara technologies and expertise span all the major digital imaging modalities including computed tomography (CT), magnetic resonance imaging (MRI), digital X-ray, mammography, ultrasound, echo-cardiology, angiography, nuclear medicine, positron emission tomography (PET) and fluoroscopy. Cedara medical imaging offerings are used in all aspects of clinical imaging workflow including the capture of a patient's digital image; the archiving, communication and manipulation of digital images; sophisticated clinical applications to analyze digital images; and the use of imaging in minimally-invasive surgery. For additional information, visit our website at www.cedara.com.
Merge Healthcare is a market leader in the development and delivery of medical imaging and information management software and services. With over twenty years of leadership in the medical imaging and healthcare information technology markets, Merge Healthcare provides innovative solutions for both OEM and the end-user healthcare markets. We custom engineer clinical and imaging applications and development tools that are on the forefront of medicine and its use of medical imaging for OEM and international customers. We develop innovative medical imaging software solutions that support end-to-end business and clinical workflow for radiology department and specialty practices, imaging centers and hospitals. Our innovative software solutions use leading-edge imaging software technologies that accelerate market delivery for our OEM customers, while our end-user solutions improve our customers' productivity and enhance the quality of patient care they provide. For additional information, visit our website at www.merge.com.
All trademarks appearing in this release are the property of Cedara Software Corp. and/or Merge Healthcare.
|
Attn: Beth Frost-Johnson
Merge Healthcare
6737 West Washington St.
Suite 2250
Milwaukee, WI 53214
|
|
|
|
|
|
| Except for the historical information herein, the matters discussed in this news release include forward-looking statements that may involve a number of risks and uncertainties. When used in this press release, the words “will,” “believes,” “intends,” “anticipates,” “expects” and similar expressions are intended to identify forward-looking statements. Actual results could differ materially from those expressed in, or implied by, the forward-looking statements based on a number of factors, including, but not limited to, the uncertainty created by, the adverse impact on relationships with customers, potential customers, suppliers and investors potentially resulting from, and other risks associated with, the changes in the Company’s senior management; costs, risks and effects of the investigation by the Audit Committee of the Board of Directors; the impact of the restatement of financial statements of the Company and other actions that may be taken or required as a result of such restatement; the Company's inability to timely file reports with the Securities and Exchange Commission; risks associated with the Company's inability to meet the requirements of The NASDAQ Stock Market for continued listing, including possible delisting; costs, risks and effects of legal proceedings and investigations, including the informal, non-public inquiry being conducted by the Securities and Exchange Commission and class action, derivative, and other lawsuits; risks in product and technology development, market acceptance of new products and continuing product demand, the impact of competitive products and pricing, ability to integrate acquisitions, changing economic conditions, credit and payment risks associated with end-user sales, dependence on major customers, dependence on key personnel, and other risk factors detailed in the Company’s filings with the Securities and Exchange Commission. Except as expressly required by the federal securities laws, the Company undertakes no obligation to update such factors or to publicly announce the results of any of the forward-looking statements contained herein to reflect future events, developments, or changed circumstances, or for any other reason.
|
|
|
